Dr. Yvonne Greenstreet stands as a trailblazer in the global pharmaceutical industry, recognized as one of the 100 Reputable Women of African Descent 2025. As the CEO of Alnylam Pharmaceuticals, she has played a pivotal role in revolutionizing RNA interference (RNAi) therapeutics, leading the development of groundbreaking medicines that transform patient care worldwide.
Born in London to a Ghanaian mother and an English father, Dr. Greenstreet’s early years were shaped by a dynamic cultural and academic environment. Her parents, both professors at the University of Ghana, instilled in her a deep passion for education and excellence. Returning to the UK for her studies, she pursued a Bachelor of Medicine and Bachelor of Surgery (MBChB) from the University of Leeds, followed by an MBA from INSEAD Business School in France—an academic foundation that laid the groundwork for her illustrious career.
Dr. Greenstreet’s journey in healthcare began as a physician specializing in obstetrics and gynecology in the UK. However, her drive to make a broader impact led her to transition into the pharmaceutical industry in 1992 with Glaxo, later GlaxoSmithKline (GSK). Over 18 years, she ascended to leadership roles, including Senior Vice President and Chief of Strategy for Research and Development. Her expertise and strategic vision later took her to Pfizer, where she led a $16 billion division as Senior Vice President and Head of Medicines Development.
In 2016, she joined Alnylam Pharmaceuticals as Chief Operating Officer (COO), and by 2021, she became the company’s CEO, making history as one of the few Black women leading a major biopharmaceutical company. Under her leadership, Alnylam has achieved major milestones, including the FDA approval of AMVUTTRA, the first second-generation RNAi therapeutic, alongside successful commercial launches of ONPATTRO, GIVLAARI, and OXLUMO. These advancements have reinforced Alnylam’s position as a leader in RNAi therapeutics, significantly impacting the lives of patients suffering from rare diseases.
Dr. Greenstreet’s contributions have not gone unnoticed. In 2024, she was named the Healthcare Businesswomen’s Association Woman of the Year, and she has been featured among Fast Company’s 100 Most Creative People in Business. Her recognition extends beyond her executive roles, as she actively contributes to influential boards, including the Bill and Melinda Gates Foundation Scientific Advisory Committee, the Discovery Council of Harvard Medical School, and the Biotechnology Industry Organization (BIO) Health Section Governing Board.
Her success story serves as an inspiration for women of African descent globally, demonstrating resilience, innovation, and leadership in a competitive industry. As one of the 100 Reputable Women of African Descent 2025, Dr. Yvonne Greenstreet continues to break barriers, champion diversity, and drive medical advancements that redefine the future of healthcare.
Leave a comment